Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels
Anna Lisa Gündner, Gonzalo Durán-Pacheco, Silke Zimmermann, et al.
Neurobiology of Disease (2018) Vol. 121, pp. 205-213
Closed Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Glucocerebrosidase and its relevance to Parkinson disease
Jenny Do, Cindy E. McKinney, Pankaj Sharma, et al.
Molecular Neurodegeneration (2019) Vol. 14, Iss. 1
Open Access | Times Cited: 249
Periphery and brain, innate and adaptive immunity in Parkinson’s disease
Ashley S. Harms, Sara A. Ferreira, Marina Romero‐Ramos
Acta Neuropathologica (2021) Vol. 141, Iss. 4, pp. 527-545
Open Access | Times Cited: 207
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Irina Alecu, Steffany A. L. Bennett
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 200
LRRK2 modifies α-syn pathology and spread in mouse models and human neurons
Gregor Bieri, Michel Brahic, Luc Bousset, et al.
Acta Neuropathologica (2019) Vol. 137, Iss. 6, pp. 961-980
Open Access | Times Cited: 164
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Laura Smith, Anthony H.V. Schapira
Cells (2022) Vol. 11, Iss. 8, pp. 1261-1261
Open Access | Times Cited: 135
Lysosomal dysfunction in neurodegeneration: emerging concepts and methods
Vinod Udayar, Yu Chen, Ellen Sidransky, et al.
Trends in Neurosciences (2022) Vol. 45, Iss. 3, pp. 184-199
Open Access | Times Cited: 131
Pathogenesis of Parkinson’s Disease
Bin Xiao, Zhidong Zhou, Yinxia Chao, et al.
Neurologic Clinics (2025)
Closed Access | Times Cited: 2
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review
Tapan Behl, Gagandeep Kaur, Ovidiu Frăţilă, et al.
Translational Neurodegeneration (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 66
The Mutation Matters: CSF Profiles of GCase , Sphingolipids, α‐Synuclein in PD GBA
Stefanie Lerche, Claudia Schulte, Isabel Wurster, et al.
Movement Disorders (2021) Vol. 36, Iss. 5, pp. 1216-1228
Open Access | Times Cited: 61
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease
Shirley Yin-Yu Pang, Rachel Lo, Philip Wing‐Lok Ho, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 45
Glucocerebrosidase mutations and Parkinson disease
Sophia R.L. Vieira, Anthony H.V. Schapira
Journal of Neural Transmission (2022) Vol. 129, Iss. 9, pp. 1105-1117
Open Access | Times Cited: 39
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Xuxiang Zhang, Heng Wu, Beisha Tang, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Margaux Teil, Marie-Laure Arotçarena, Emilie Faggiani, et al.
Biomolecules (2020) Vol. 10, Iss. 3, pp. 391-391
Open Access | Times Cited: 55
Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
Céline Galvagnion, Frederik Ravnkilde Marlet, Silvia Cerri, et al.
Brain (2021) Vol. 145, Iss. 3, pp. 1038-1051
Open Access | Times Cited: 54
New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Konstantin Senkevich, Uladzislau Rudakou, Ziv Gan‐Or
Neuropharmacology (2021) Vol. 202, pp. 108822-108822
Closed Access | Times Cited: 53
GBA-associated PD: chances and obstacles for targeted treatment strategies
Günter U. Höglinger, Claudia Schulte, Wolfgang H. Jost, et al.
Journal of Neural Transmission (2022) Vol. 129, Iss. 9, pp. 1219-1233
Open Access | Times Cited: 35
Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
Gaetano Giuffrida, Uroš Markovic, Annalisa Condorelli, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 21
Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson’s Disease Research
Tiffany Jong, Alexandra Gehrlein, Ellen Sidransky, et al.
Journal of Parkinson s Disease (2024) Vol. 14, Iss. 1, pp. 65-78
Open Access | Times Cited: 7
GBA1-associated parkinsonism: new insights and therapeutic opportunities
Emory Ryan, Gurpreet Seehra, Pankaj Sharma, et al.
Current Opinion in Neurology (2019) Vol. 32, Iss. 4, pp. 589-596
Closed Access | Times Cited: 52
Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update—I. Hypokinetic-rigid movement disorders
K. A. Jellinger
Journal of Neural Transmission (2019) Vol. 126, Iss. 8, pp. 933-995
Closed Access | Times Cited: 43
The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s disease
Sonia Sanz Muñoz, Daniel Petersen, Frederik Ravnkilde Marlet, et al.
Biophysical Chemistry (2020) Vol. 273, pp. 106534-106534
Open Access | Times Cited: 41
GBA mutations, glucosylceramide and Parkinson's disease
Ivan Milenković, Shani Blumenreich, Anthony H. Futerman
Current Opinion in Neurobiology (2021) Vol. 72, pp. 148-154
Closed Access | Times Cited: 33
The Role of Rab Proteins in Parkinson’s Disease Synaptopathy
Arianna Bellucci, Francesca Longhena, Maria Grazia Spillantini
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1941-1941
Open Access | Times Cited: 23
Mechanisms of Glucocerebrosidase Dysfunction in Parkinson’s Disease
Diptaman Chatterjee, Dimitri Krainc
Journal of Molecular Biology (2023) Vol. 435, Iss. 12, pp. 168023-168023
Open Access | Times Cited: 15
Causal inference in drug discovery and development
Tom Michoel, Jitao David Zhang
Drug Discovery Today (2023) Vol. 28, Iss. 10, pp. 103737-103737
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top